Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Reports outline cancer study findings from J.S. Lewis and colleagues
August 28th, 2008
"Tumor uptake of copper(II)-diacetyl-bis(N-4-methylthiosemicarbazone) (copper-ATSM), a hypoxia-targeting radiopharmaceutical, assessed by PET has been found to correlate with prognosis in several human cancers. Wide clinical utility of this tracer will require its labeling with a copper radionuclide having a longer half-life than the Cu-60 used in studies to date," scientists in the United States report. "The purpose of this work was to obtain the requisite preclinical data for copper-ATSM to file an investigational new drug application, followed by a crossover comparison of PET image quality and tumor uptake with Cu-60-ATSM and Cu-64-ATSM in women with cancer of the...
Source: Women's Health Weekly (2008-08-28)
|
